Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma
- PMID: 9851753
- DOI: 10.1210/jcem.83.12.5355
Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma
Abstract
We previously reported that in Cushing's disease (CD) the ACTH- and cortisol (F)-releasing activity of Hexarelin (HEX), a GH secretagogue, is exaggerated with respect to that in normal subjects and is higher than that of human CRH (hCRH), but it is absent in Cushing's syndrome. Our aim was to extend the study about the effects of HEX (2.0 microg/kg, iv) on ACTH and F secretion in 21 patients with CD (3 men and 18 women, 16-68 yr old). Based on magnetic resonance imaging, 15 CD patients had pituitary microadenoma, and 6 had macroadenoma. The results in CD patients were compared with those in 27 normal age-matched controls (NS; 10 men and 17 women, 24-69 yr old). Basal ACTH and F levels in CD were similar in patients with microadenom (mean+/-SEM, 78.3+/-7.2 pg/mL and 237.1+/-23.6 microg/L, respectively) and macroadenoma (57.4+/-9.0 pg/mL and 196.9+/-20.1 microg/L, respectively) and were higher (P < 0.001) than those in NS (17.7+/-2.0 pg/mL and 115.3+/-6.7 microg/L, respectively). In microadenoma CD patients, HEX induced marked ACTH and F increases (delta peak, mean+/-SEM: 261.2+/-77.6 pg/mL and 226.1+/-87.2 microg/L, respectively), which were higher (P < 0.04) than those induced by hCRH (45.6+/-16.9 pg/mL and 84.6+/-25.7 microg/L, respectively). Moreover, in microadenoma CD patients, the ACTH and F responses to HEX were higher (P < 0.001) than those in NS (18.5+/-4.0 pg/mL and 36.1+/-6.8 microg/L, respectively). In macroadenoma CD patients, HEX induced a slight, but significant increase (P < 0.02) in ACTH and F levels (33.9+/-18.0 pg/mL and 89.6+/-34.3 microg/L, respectively), which was not significantly different from that elicited by hCRH (20.0+/-7.0 pg/mL and 54.8+/-21.3 microg/L, respectively). In macroadenoma CD patients, the ACTH and F responses to HEX and hCRH were, in turn, similar to those in NS. In conclusion, our findings demonstrate that the ACTH and F hyperresponsiveness to HEX is present in Cushing's disease with micro-, but not macro- ACTH-secreting pituitary adenoma. This finding agrees with other evidence pointing toward differences in the hormonal behavior between micro- and ACTH-secreting pituitary macroadenomas.
Similar articles
-
Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.J Clin Endocrinol Metab. 1997 Aug;82(8):2439-44. doi: 10.1210/jcem.82.8.4132. J Clin Endocrinol Metab. 1997. PMID: 9253314
-
Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing's disease.J Endocrinol Invest. 1999 Jan;22(1):23-8. doi: 10.1007/BF03345474. J Endocrinol Invest. 1999. PMID: 10090133
-
Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans.Neuroendocrinology. 1997 Dec;66(6):432-8. doi: 10.1159/000127269. Neuroendocrinology. 1997. PMID: 9430449 Clinical Trial.
-
Extrapituitary parasellar microadenoma in Cushing's disease.J Clin Endocrinol Metab. 1999 Aug;84(8):2912-23. doi: 10.1210/jcem.84.8.5890. J Clin Endocrinol Metab. 1999. PMID: 10443699 Review.
-
Infrasellar pituitary gangliocytoma causing Cushing's syndrome.Pituitary. 2015 Oct;18(5):738-44. doi: 10.1007/s11102-014-0595-4. Pituitary. 2015. PMID: 25183169 Review.
Cited by
-
GH secretagogues and hypothalamo-pituitary-adrenal axis.J Endocrinol Invest. 2003 Mar;26(3):190-1. doi: 10.1007/BF03345155. J Endocrinol Invest. 2003. PMID: 12809166 No abstract available.
-
Dynamic testing in Cushing's syndrome.Pituitary. 2008;11(2):155-62. doi: 10.1007/s11102-007-0079-x. Pituitary. 2008. PMID: 18034306 Review.
-
In vivo response to growth hormone-releasing peptide-6 in adrenocorticotropin-dependent Cushing's syndrome by lung carcinoid tumor is associated with growth hormone secretagogue receptor type 1a mRNA expression.J Endocrinol Invest. 2007 Apr;30(4):334-40. doi: 10.1007/BF03346301. J Endocrinol Invest. 2007. PMID: 17556872
-
Biologic activities of growth hormone secretagogues in humans.Endocrine. 2001 Feb;14(1):87-93. doi: 10.1385/ENDO:14:1:087. Endocrine. 2001. PMID: 11322506 Review.
-
Ghrelin, hypothalamus-pituitary-adrenal (HPA) axis and Cushing's syndrome.Pituitary. 2004;7(4):243-8. doi: 10.1007/s11102-005-1173-6. Pituitary. 2004. PMID: 16132204 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous